Concord Biotech stock lists at 21% premium over IPO price; share price hits Rs 900 at open
Concord Biotech, backed by the late Rakesh Jhunjhunwala’s RARE Trusts fund, started trading at 21.46% above its IPO price on Aug. 18, beating analysts’ expectations of 15%. Shares opened the day at Rs 900.05 on the BSE and NSE, compared to a public issue price of Rs 741 per share. Most experts believe that stagnant …